Literatur
Ribas A et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med. 2019; 25: 936-40
Sullivan RJ et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019; 25: 929-35
Ascierto PA et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat Med. 2019; 25: 941-946
Long GV et al. The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600-mutant melanoma: updated efficacy and safety from parts 1 and 2 of MBI-i. J Clin Oncol. 2019; 37 (Suppl): Abstr 9531
Hurwitz M et al. Baseline tumor immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. J Clin Oncol. 2019; 37 (Suppl): Abstr 2623
Long GV et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/ KEYNOTE-252 study. J Clin Oncol. 2018; 36 (Suppl): Abstr 108
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hauschild, A. Fernmetastasiertes Melanom: neue Therapiestudien. hautnah dermatologie 36 (Suppl 1), 19–23 (2020). https://doi.org/10.1007/s15012-019-0001-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15012-019-0001-z